For research use only. Not for therapeutic Use.
Rebamipide mofetil is an orally active proagent of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner[1].
| Catalog Number | I035472 |
| CAS Number | 1527495-76-6 |
| Synonyms | 2-morpholin-4-ylethyl 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoate |
| Molecular Formula | C25H26ClN3O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H26ClN3O5/c26-19-7-5-17(6-8-19)24(31)28-22(25(32)34-14-11-29-9-12-33-13-10-29)15-18-16-23(30)27-21-4-2-1-3-20(18)21/h1-8,16,22H,9-15H2,(H,27,30)(H,28,31) |
| InChIKey | BVZOVIJSRAGQLP-UHFFFAOYSA-N |
| SMILES | C1COCCN1CCOC(=O)C(CC2=CC(=O)NC3=CC=CC=C32)NC(=O)C4=CC=C(C=C4)Cl |
| Reference | [1]. Cho, Eui Hwan, et al.Pharmaceutical composition comprising rebamipide precursor for oral administration for preventing or treating immune disease and metabolic disease.WO2017138717A1. |
